What We're Reading: Anthem Reduces Premium Hikes; Second Gene Therapy; California Wildfires
Anthem Will Reduce Planned Premium Hikes
After facing scrutiny from California regulators, Anthem Blue Cross will ease up 2 planned premium increases for 2018.
Second Gene Therapy Gets Endorsed
An FDA advisory committee has endorsed another gene therapy. The committee voted unanimously, 16-0, for a therapy to treat an inherited disorder that causes a progressive form of blindness,
California Wildfires Strain Medical Services
The fires in California have forced hospital evacuations, destroyed medical offices, and increased the number of patients that need to be seen at the remaining hospitals and health centers that are open.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025